Media | GEn1E Lifesciences

Stay Updated

News, Publications & Events

Stay updated on groundbreaking achievements, explore noteworthy publications, and mark your calendar for upcoming events that shape our collective story.

BARDA announces new partnerships to treat serious outcomes of infectious disease

GEn1E Lifesciences Adds NextGen Selective Immunomodulator Target to Portfolio, Broadens Pipeline

GEn1E Lifesciences Announces Partnership with BARDA to Advance its AI-powered Endotyping Program for ARDS Patients to Further Accelerate its Novel, Lead Compound GEn-1124

UMB, in partnership with alumni, wants to commercialize rare disease treatments

Meet GEn1E, the biotech bringing p38alpha kinase drugs to inflammatory diseases

Silicon Valley is throwing money behind Covid-19 efforts, hoping for results

Inflect Health Expands its Strategic Partnership with GEn1E Lifesciences to Combat Rare & Inflammatory Diseases

Inside the Silicon Valley ‘brain trust’ taking aim at COVID-19

New Hope for Overlooked Diseases

Stanford alumni founders tackle COVID-19 with StartX task force

The genies in medicine that work to solve ARDS

UMB licenses technology to Y Combinator-backed biotech startup

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Xiaobo Yang, MD., Yuan Yu, MD., Jiqian Xu, MD., Prof Huaqing Shu, MD., Prof Jia'an Xia, MD., Prof Hong Liu, MD; et al.

Covid-19 in Critically Ill Patients in the Seattle Region — Case Series

Pavan K. Bhatraju, M.D., Bijan J. Ghassemieh, M.D., Michelle Nichols, M.D; et al

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

Giacomo Grasselli, MD; Alberto Zangrillo, MD; Alberto Zanella, MD; et al

Publication by Advisor

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

Mehdi Bouhaddou, Danish Memon, Bjoern Meyer, ..., Danielle L. Swaney, Pedro Beltrao, Nevan J. Krogan

Publication by Advisor

p38 MAPK inhibition: A promising therapeutic approach for COVID-19

Grimes, J. M., & Grimes, K. V.

42nd Annual J.P. Morgan Healthcare Conference

January 8-11, 2024